UniProtKB/Swiss-Prot Q9NP85: Variant p.Glu237Gln

Podocin
Gene: NPHS2
Feedback?

Variant information Variant position:

237 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Glutamate (E) to Glutamine (Q) at position 237 (E237Q, p.Glu237Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and acidic (E) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs146906190 [ dbSNP | Ensembl ]

Sequence information Variant position:

237 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

383 The length of the canonical sequence.
Location on the sequence:

LVQTTMKRLLAHRSLTEILL E RKSIAQDAKVALDSVTCIWG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LVQTTMKRLLAHRSLTEILLERKSIAQDAKVALDSVTCIWG

Mouse                         LVQTTMKRLLAHRSLTEILLERKSIAQDVKVALDAVTCIWG

Rat                           LVQTTMKRLLAHRSLTEILLERKSIAQDVKVALDSVTCVWG

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 383	Podocin
Topological domain	124 – 383	Cytoplasmic
Alternative sequence	179 – 246	Missing. In isoform 2.

Literature citations
NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence.
Weber S.; Gribouval O.; Esquivel E.L.; Moriniere V.; Tete M.J.; Legendre C.; Niaudet P.; Antignac C.;
Kidney Int. 66:571-579(2004)
Cited for: VARIANTS NPHS2 THR-29; LEU-118; CYS-168; HIS-168; SER-168; VAL-172; THR-208; 236-LEU--ARG-238 DEL; SER-238 AND GLU-260; VARIANTS VAL-61; GLN-237 AND VAL-242; A molecular genetic analysis of childhood nephrotic syndrome in a cohort of Saudi Arabian families.
Al-Hamed M.H.; Al-Sabban E.; Al-Mojalli H.; Al-Harbi N.; Faqeih E.; Al Shaya H.; Alhasan K.; Al-Hissi S.; Rajab M.; Edwards N.; Al-Abbad A.; Al-Hassoun I.; Sayer J.A.; Meyer B.F.;
J. Hum. Genet. 58:480-489(2013)
Cited for: VARIANTS NPHS2 39-GLN--LEU-383 DEL; PRO-138; HIS-168; MET-180; PHE-254 AND GLU-260; VARIANT GLN-237; NPHS2 mutations in steroid-resistant nephrotic syndrome: a mutation update and the associated phenotypic spectrum.
Bouchireb K.; Boyer O.; Gribouval O.; Nevo F.; Huynh-Cong E.; Moriniere V.; Campait R.; Ars E.; Brackman D.; Dantal J.; Eckart P.; Gigante M.; Lipska B.S.; Liutkus A.; Megarbane A.; Mohsin N.; Ozaltin F.; Saleem M.A.; Schaefer F.; Soulami K.; Torra R.; Garcelon N.; Mollet G.; Dahan K.; Antignac C.;
Hum. Mutat. 35:178-186(2014)
Cited for: VARIANTS NPHS2 SER-97; PRO-107; SER-122; VAL-175; TYR-183; LYS-281; LYS-296; VAL-309; ILE-315 AND GLY-333; VARIANTS LEU-20; GLN-237 AND GLN-264;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.